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Abstract
Transiently populated oligomers formed en route to amyloid fibrils may constitute the most toxic 
aggregates associated with many amyloid-associated diseases. Most nucleation theories used to 
describe amyloid aggregation predict low oligomer concentrations and do not take into account 
free energy costs that may be associated with structural rearrangements between the oligomer and 
fiber states. We have used isotope labeling and two-dimensional infrared spectroscopy to 
spectrally resolve an oligomeric intermediate during the aggregation of the human islet amyloid 
protein (hIAPP or amylin), the protein associated with type II diabetes. A structural rearrangement 
includes the F23G24A25I26L27 region of hIAPP, which starts from a random coil structure, evolves 
into ordered β-sheet oligomers containing at least 5 strands, and then partially disorders in the 
fibril structure. The supercritical concentration is measured to be between 150 and 250 μM, which 
is the thermodynamic parameter that sets the free energy of the oligomers. A 3-state kinetic model 
fits the experimental data, but only if it includes a concentration independent free energy barrier 
>3 kcal/mol that represents the free energy cost of refolding the oligomeric intermediate into the 
structure of the amyloid fibril; i.e., “oligomer activation” is required. The barrier creates a 
transition state in the free energy landscape that slows fibril formation and creates a stable 
population of oligomers during the lag phase, even at concentrations below the supercritical 
concentration. Largely missing in current kinetic models is a link between structure and kinetics. 
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Our experiments and modeling provide evidence that protein structural rearrangements during 
aggregation impact the populations and kinetics of toxic oligomeric species.
Graphical Abstract
INTRODUCTION
Amyloid diseases like Alzheimer’s, Parkinson’s, and type II diabetes are all associated with 
the formation of β-sheet rich amyloid fibrils and plaques.1 Mounting evidence suggests that, 
for many amyloid diseases, prefibrillar intermediates or oligomeric assemblies are more 
toxic than mature plaques.2,3 For this reason, it is important to characterize the structures, 
lifetimes, and populations of intermediate species along the aggregation pathway. Kinetics 
experiments are the most common method for studying transient species. By modeling the 
experimental aggregation kinetics, one retrieves the energetics of the free energy pathway 
that set the thermodynamic parameters responsible for driving the aggregation process.
Since the kinetics of fibril formation are almost always sigmoidal, amyloid fibril formation 
is commonly thought to be a nucleated polymerization phenomenon. Many variations of 
nucleation models have been proposed to explain the shape, lag time, and rise of the 
sigmoidal curve.4–26 The key commonality between these models is a nucleation event in 
which a certain number of proteins (the critical nucleus size, n) assemble into an oligomer 
that, once formed, templates the addition of monomers to grow into a fibril.4–26 Since the 
oligomer is an assembly of proteins, its free energy depends on concentration. Thus, in these 
models, it is the stability of the nucleus that largely dictates the kinetics, because the free 
energy of the nucleus sets the likelihood for fibril formation and thus the lag time of the 
sigmoidal kinetics.4–7 Models often include fragmentation effects and secondary nucleation 
events to better match the steepness of the sigmoidal rise.6,7,9,16,19,20,22–26
Missing from nucleated polymerization models of amyloid formation are free energy 
barriers that would be caused by structural changes of the oligomers, even though there is 
evidence that many amyloid oligomers or other intermediates have structures that differ from 
the parallel β-sheets of fibrils. α-Helical intermediates have been detected during the lag 
phase for amyloid formation in amyloid-β, α-synuclein, and human islet amyloid 
polypeptide (hIAPP, also known as amylin), by CD,27–29 NMR29,30 EPR,31 and 
fluorescence and neutron reflectometry32 studies. There is evidence for antiparallel β-sheet 
structure in intermediates of amyloid-β,33 α-synuclein,34 and the SH3 domain.35,36 
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Cylindrin structures formed from fragments of αB-Crystallin have been crystallized.37 
While there is not yet an atomic structure for both an oligomer and fibril for a single 
amyloid protein, the structural properties of oligomers or other intermediates examined so 
far often do not resemble known structures of amyloid fibrils.27–31,33–37 Thus, it appears that 
many amyloid forming proteins and polypeptides must undergo a structural rearrangement 
in order to transition from an oligomeric state to the final state of the amyloid fibril. A 
structural rearrangement suggests a change in free energy. In other words, if the oligomers 
have a structure that differs from that of the fibrils, then there must be a free energy change 
associated with “refolding” the oligomeric protein structures into the structure of the fibril. 
We use the term “folding” to refer to protein secondary and tertiary changes analogous to 
those studied in the protein “folding” community, but in the context of an assembly of 
proteins with interprotein contacts.
In this manuscript we use pulse shaping 2D IR spectroscopy and 13C18O isotope labeling to 
investigate the structure of an intermediate in the aggregation pathway of hIAPP and model 
the kinetics of the evolving spectra to link the thermodynamics to the molecular structure. 
hIAPP is a 37-residue hormone which is cosecreted with insulin from pancreatic β -cells.38 
hIAPP normally plays a role in regulating metabolism,39,40 but aggregates in type II 
diabetes.41,42 The aggregation of hIAPP into amyloid plaques is correlated with the onset of 
type II diabetes, and cell viability studies have pointed to oligomeric intermediates as the 
toxic species.2,3 We isotope label all 5 residues comprising the 23–27 FGAIL region of 
hIAPP, because it falls within the 20–29 SNNFGAILSS sequence that is crucial to the 
formation of amyloid plaques.43,44 Mutations in this region slow or prohibit fibril formation.
45–47
 Fragments of 20–29, or subsets of these residues, form amyloid plaques in vitro,44,48,49 
and natural variations among species correlate with the propensity of contracting type 2 
diabetes.43 Moreover, using single isotope labels, we previously observed interstrand 
couplings in this region that we assigned to an oligomeric intermediate.50 The intermediate 
is not well-resolved from the fibrils without isotope labeling.51 The multiple labeling 
scheme used here creates 2D IR spectra that are also sensitive to dihedral angles, enabling 
the spectra to be simulated with model structures. Multiple labels also increase the signal 
strength,52,53 allowing us to lower the polypeptide concentration, and thereby put bounds on 
the supercritical concentration of the oligomer. We find that the spectral kinetics can only be 
fit with a nucleated polymerization model when a concentration independent free energy 
barrier is included between the nucleus and fibril states. The free energy necessary to 
rearrange the structure of the oligomer into the structure of the fibril slows aggregation, 
lengthening the lag time, and stabilizing the population of oligomers. To deduce that a 
barrier exists, one needs to monitor the kinetics of both the oligomer and fibril. Thus, we 
provide experimental evidence that nucleated polymerization models should also include 
free energy barriers associated with structural rearrangements.
MATERIALS AND METHODS
A full description of the methods used is given in the SI, Materials and Methods. Briefly, 
13C18O FGAIL labeled hIAPP and unlabeled hIAPP were synthesized using previously 
published methods.54 hIAPP was dissolved in deuterated hexafluoroisopropanol (HFIP-d) in 
order to substitute exchangeable protons. Samples were lyophilized to remove HFIP-d prior 
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to experiments. The addition of 20 mM phosphate D2O buffer, pD 7, was used to initiate 
aggregation. Final peptide concentrations used for FGAIL labeled hIAPP were between 150 
and 500 μM, and isotope dilution experiments were carried out using 20% FGAIL labeled 
peptide with a total hIAPP concentration of 500 μM. Rapid scan 2D IR spectra were 
collected as previously described.55 Mass-action kinetic simulations were carried out using a 
modified version of the simplified nucleated autocatalytic polymerization model described 
by Hill,8 and detailed below. Spectral modeling was performed using the molecular snapshot 
approach.56,57 Additional details are provided in the SI. 2D IR and kinetic simulations were 
carried out in MATLAB.
RESULTS
Rapid scan 2D IR spectroscopy, made possible by pulse shaping,58–60 was used to monitor 
real-time aggregation kinetics in hIAPP samples with all five FGAIL residues 13C18O 
labeled. Figure 1 shows data collected at 500 μM concentration. Hundreds of 2D IR spectra 
were collected as a function of time. Three representative spectra are shown, focusing on the 
portion of the spectrum that arises from the isotope labeled FGAIL region. These three were 
chosen to represent the earliest, middle, and late stages of aggregation at T = 0, 20, and 80 
min in Figures 1a, b, and c, respectively. The spectra differ in their frequencies and 2D 
lineshapes, which indicates that the couplings, and therefore the structure, of the FGAIL 
region is changing during the course of aggregation. Each spectrum consists of a 
fundamental (red) and overtone (blue) transition. At T = 0 (during the lag phase), the spectra 
are very broad along the diagonal, have an anharmonic shift (the difference in frequency 
between the two peaks along the ωprobe axis) of Δ = 25 cm−1, and the frequency of the 
maximum absorption is near 1583 cm−1, which are all consistent with the FGAIL sequence 
having a disordered structure typical of a random coil. At T = 20 min (later in the lag phase), 
the spectra are narrower, have a smaller anharmonic shift of Δ = 15 cm−1, and a peak 
frequency of ωprobe = 1565 cm−1. Reduced anharmonicity is associated with stronger 
coupling and more ordered β-sheet structures.61 At T = 80 min the anharmonic shift is Δ = 
15 cm−1, and the peak frequency even lower at ωprobe = 1558 cm−1. The spectra at T = 20 
and 80 min have frequency dependent anharmonic shifts. Spectral narrowing and <25 cm−1 
anharmonic shifts are signatures of exciton delocalization caused by coupling between 
multiple peptides, and so the spectra at T = 20 and 80 min must be of peptides associating 
into protein assemblies with defined structures. The frequency dependent anharmonicity and 
“Z-pattern” of the spectra is consistent with β-sheet structures.62 No fibrils are observed in 
TEM collected during the lag phase (Figure S1), and so we conclude that the 3-spectra 
correspond to disordered monomers, β-sheet oligomers, and the final amyloid fibrils, con s i 
s tent with our previous publi c a t i o ns on hIAPP.50,51,55,63–66
To more fully illustrate the changes in coupling as a function of aggregation time, we plot 
the diagonal cut through hundreds of the time dependent spectra, each normalized to the 
peak intensity, to create the kinetic plot shown in Figure 1d. Dashed lines illustrate the 
connection between the maximum of the peak frequency in the spectra in Figure 1a with the 
kinetic plot. Three distinct states are observed in the kinetics, each of which were 
represented by the 2D spectra in Figure 1a–c. The 1583 cm−1 peak of the monomer shifts 
within 10 min to 1565 cm−1, the peak of the oligomer, which remains for nearly an hour, 
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until the spectrum transitions to 1558 cm−1, the frequency of the fibril. The spectra no longer 
evolve after the third state, as determined by measurements made over 1 day later (see SI).
Figure 2 also shows the kinetics of the 500 μM data from Figure 1, along with kinetics 
collected at 250 and 150 μM concentrations. The maximum intensity for each probe 
wavelength is plotted rather than the diagonal cut, which gives higher signal-to-noise, and is 
why the frequencies are shifted a few cm−1 from Figure 1. Superimposed on each plot is a 
trace of the intensity at 1620 cm−1, which monitors the overall population of the β-sheets in 
the amyloid fibrils by signal from the 32 unlabeled 12C16O amino acids.67 The 1620 cm−1 
signal is analogous to a thioflavin-T experiment, as we have previously demonstrated,51 
which is why it exhibits a sigmoidal shape. The data at 250 μM (Figure 2b) exhibits the 
same three kinetic states observed at 500 μM. Note that the transition between the 
intermediate state and the final state in the 500 and 250 μM data occurs at about the half-rise 
time of the sigmoidal β-sheet trace. In other words, the intermediate oligomer is present 
throughout the lag phase. In contrast, the data at 150 μM only exhibit 2 of the 3-states; the 
monomers and the fibrils are observed, but not the oligomers. Thus, at 250 and 500 μM, we 
observe an intermediate FGAIL structure that is not observed experimentally at 150 μM. 
Based on our signal-to-noise, the intermediate state must be <5% of the total protein 
population, if present at all in the 150 μM data. Additional data is provided in the Supporting 
Information that demonstrates the experimental reproducibility, puts error bars on the 
frequencies, and tests the effects of interstrand and intrastrand couplings through isotope 
dilution experiments.
Structural Assignments and Simulations of 2D IR Spectra
In this section, we simulate 2D IR spectra for each of the 3 states that are consistent with 
known experimental data. In the next section, these spectra are combined with the kinetic 
model to reproduce the experimental data. To do so, we use an excitonic Hamiltonian that 
includes transition dipole coupling68 and nearest neighbor couplings from the map of Jansen 
et al.,69 diagonal disorder, and a homogeneous line width of 10 cm−1 (fwhm). The 
Hamiltonian only includes the 5-residues in the FGAIL region, as the 13C18O labeled 
residues are effectively decoupled from the unlabeled residues in the rest of the protein.
The modeled spectra and corresponding structures are shown in Figure 3, each of which 
match the experimental frequencies, line widths, and anharmonic shifts from Figure 1 to 
within a few wavenumbers. We modeled the T = 0 spectrum as a disordered monomer by 
creating 500 unique structures from a self-avoiding chain model and dihedral angles taken 
from the Top 500 database nonsecondary structure distribution.70 Since the time resolution 
of 2D IR spectroscopy is about 1 ps, and we expect no protein structural dynamics to occur 
on that time scale, the ensemble averaged 2D IR spectrum is generated simply by calculating 
the spectrum for each individual structure and then summing.56,57,71,72 Thus, the structure of 
the FGAIL segment of hIAPP during the first few minutes of aggregation is consistent with 
a highly disordered or random coil structure.
The intermediate state at T = 20 min was simulated using a 5-stranded parallel β-sheet. All 
five FGAIL residues were modeled in a β-sheet conformation, consistent with previous 
single isotope labeled experiments that were consistent with inregister coupling.50 β-Sheets 
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with fewer than 5 strands are not consistent with the experimental data, but we cannot rule 
out β-sheets with more strands if there is a corresponding increase in structural disorder that 
creates diagonal and off-diagonal disorder in the vibrational Hamiltonian. The estimated 
oligomer size range overlaps with the size of oligomers detected by photochemcially 
induced cross-linking and by ion mobility mass spectroscopy.73,74
The fibril state was simulated with residues F and G disordered and residues A, I, and L as 
part of a parallel β-sheet. This structure is consistent with the solid state NMR model for the 
hIAPP fibril with which previous 2D IR measurements and simulations were in agreement.
75,76
 The F and G residues used the same self-avoiding chain model and dihedral angle 
distribution as for the monomer above. A fully ordered FGAIL region produces too low of a 
frequency. Additional details of the modeling are provided in the SI.
The simulations capture the essential features of the experimental 2D IR spectra. Thus, we 
conclude that the three states observed in the experiments are consistent with disordered 
monomers, an oligomeric nucleus in which the FGAIL region of at least 5 polypeptides that 
have assembled into an ordered β-sheet, and the fibril structure in which part of the FGAIL 
region adopts a disordered loop. We note that the negative couplings measured in our 
previous publication for the oligomer might be generated by structures other than the 
canonical parallel β-sheet modeled here, such as out of register parallel or perhaps 
antiparallel β-sheets.77,78 Additional labeling schemes would be needed to test these 
possible structures.78 Better agreement to experiment might also be obtained from molecular 
dynamics simulations of the structures and more sophisticated line shape theories.72 
Regardless of the precise structure of the FGAIL β-sheet, the 2D IR spectra can only be 
explained by a well-ordered β-sheet, which is the most important finding for our conclusions 
regarding the free energy landscape. Below, we use the simulated spectra in conjunction 
with a mass action kinetic model to simulate the experimental kinetic plots.
Kinetic Model
We now turn to modeling the population kinetics. We employ a nucleated polymerization 
mass action kinetic model, similar to others used by many researchers, 4–6,8,11,13,16,19,24,25 
to describe the observed kinetics of monomer, oligomer, and fibril as a function of peptide 
concentration. Before presenting the equations that describe our model, we provide a 
graphical summary as an overview, given in Figure 4. In this model, monomeric peptides 
(orange) are allowed to form an oligomeric species of size n (green ovals). As a 
simplification, the peptides assemble in a concerted manner with forward and reverse rate 
constants of kolig and k−olig. To form fibrils, this oligomer must undergo a conformational 
change with a free energy cost of ΔG‡ (green, parallelogram), after which it can accept an 
additional monomer and become “locked” into a fibril conformation (blue, parallelogram). 
Once locked, it can “seed” fibril growth by templating monomers with a bimolecular rate 
constant of k+. Fibrils are allowed to fragment, generating additional ends for templating 
monomers, and thereby speeding up aggregation in an autocatalytic manner.6,7,9,19,22–26 
Fragmentation is typically needed in aggregation models to account for the steepness of the 
sigmoidal curve, and is believed to result from mechanical instability of the fibrils.19,79 In 
the case where the ΔG‡ = 0, the above mechanism becomes equivalent to previous 
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nucleation models.8,13 Note that Figure 4 is drawn schematically; the relative free energies 
depend on concentration (as discussed later in Figure 6).
The starting point for deriving the kinetic model of Figure 4 comes from the following set of 
kinetic steps:
(1)
where monomers are M, “oligomers” are Oi where i ranges from 2 to n, “fibril” species are 
Fi with i ranging from n + 1 to ∞, and n is the critical nucleus size. The substantive 
difference between species defined as oligomeric versus fibrillar is the difference in stability 
provided by their respective dissociation rate constants (all of the forward second order 
reaction rate constants, k+, are assumed to be equal). These stabilities can be conveniently 
quantified using the following definitions for the apparent equilibrium dissociation 
constants:
(2)
where ccrit and csup are called the critical and supercritical concentrations, respectively.4,13 
The critical concentration is sometimes called the solubility, as it represents the maximum 
concentration of monomers that can exist in equilibrium with a very long fibril (because fi ≅ 
fi+1, where fi represents the concentration of fibrils of size i).4 As the monomer cannot stably 
exist in excess of ccrit, all peptides present above this concentration will tend toward 
aggregation into a fibril, and thus the critical concentration gives the concentration above 
which fibrils become thermodynamically stable. A similar interpretation exists for the 
supercritical concentration and sets the concentration at which the oligomers become more 
stable than the monomer. Generally, ccrit < csup. Special significance is given to the species 
of size n, called the critical nucleus, or just nucleus, owing to it being the point at which the 
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dissociation equilibrium constants change discontinuously. This can generate an extremum 
in concentration as a function of species size near n, leading to the nucleus often being 
interpreted as a “barrier” to aggregation. In the present model, a significant deviation from 
more conventional nucleated polymerization models is introduced in the form of an activated 
state, , that the nucleus must visit prior to forming a fibrillar species. 
k+a and k−a are the forward and reverse rate constants for formation of the activated species. 
This additional reaction step may be approximately accounted for using the above activation 
barrier expression (detailed in SI). This process is similar in many respects to the “monomer 
activation” model20,80,81 where the rate-limiting step of aggregation is posited to be a 
conformational change in the monomeric species before growth can occur,82 except that in 
the present case the conformational change is occurring for an n-mer rather than the 
monomer. Thus, we dub our scheme an “oligomer activation” model.
Since the reported 2D IR spectra only resolve three distinct states, we reduce the complexity 
of the kinetic model to 3-states with the following approximations: fast pre-equilibration of 
oligomers8,13 that gives a concerted mechanism for formation of the nucleus, the extremum 
approximation for the nucleus cn ≈ f n+1,8 and the assumption that . 
With these approximations, we arrive at the following coupled rate equations (detailed in 
SI):
(3)
With this concerted mechanism for formation of the nucleus, cn becomes representative of 
all oligomeric species and is referred to henceforth as the “oligomer”. The total peptide 
concentration is represented by ctot and fibril species are collectively represented by f, which 
can only form by one of two mechanisms: conversion of an oligomer to a fibril, represented 
by the first term in the equation df/dt for, or by fragmentation, represented by the second 
term. Fragmentation allows fibrils to spontaneously disassociate, generating two new ends 
upon which monomers can attach. “Secondary nucleation” events, such as fragmentation, 
are well-known to be a cause of sigmoidal aggregation kinetics through autocatalysis,5,6,19 
and fragmentation has been invoked in the past to describe the kinetics of hIAPP 
aggregation.11 A fragmentation rate of k
−
 may be thought of as an upper limit 
approximation, and is the value used in the closed-form fragmentation model by Knowles et 
al.19 The free parameters in the model are n and ΔG‡. Because we will not be matching 
absolute times with the experiment, k+ is arbitrary and set to 1 everywhere. The reverse rate 
for fibril growth, k
−
, is set using a previous experimental estimate of 100 nM for ccrit.83 In 
order to set k
−olig, we estimate a value for csup based on the present 2D IR data. The signal 
from oligomers dominates during the lag phase at 250 μM, but are not detectable at 150 μM. 
As the 2D IR signal for a β-sheet oligomer should grow linearly or faster with the size of the 
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sheet, ncn < c1 at 150 μM. Assuming detailed balance between monomers and oligomers is 
achieved during the lag phase, this implies that . As only monomers are 
visible at 150 μM and the noise level is ~10%, monomers must represent at least 90% of the 
peptide present, making 135 μM the lower limit for the supercritical concentration. We 
choose 250 μM as an upper estimate for csup because oligomers dominate the signal during 
the lag phase at both 250 and 500 μM. Previous estimates for the size of the nucleus range 
from n = 3 to 20, so we have restricted our analysis to this range.11,84 Finally, we note that 
the pre-equilibration approximation overestimates the rate at which monomers convert to 
oligomers since, for example, at ctot = csup the initial slope of the monomer concentration is 
 while for the more general model in eq 1 the initial slope would be 
. Nonetheless, this fact has little consequence for our interpretation, which focuses 
on the transition between oligomer and fibril.
Simulations of the Experimental Structural Kinetics
In the above sections, we have defined the dominant FGAIL structures populated during 
each of the 3-phases, created 2D IR spectra for each state, and outlined a kinetic model that 
is similar to previous models but contains an additional free energy barrier. In this section, 
we use these results to create kinetic plots for comparison to experiment and test the 
influence, if any, that a free energy barrier plays in the kinetics.
Shown in Figure 5a–d are the time-dependent mass fractions (i.e., populations) of monomers 
(blue), oligomers (red), and fibrils (yellow) as predicted from the kinetic model for initial 
protein concentrations of 150 and 500 μM with n = 10. Figure 5a,b presents results for ΔG‡ 
= 0, and Figure 5c,d for ΔG‡ = 6 kcal/mol. All the simulated kinetics begin with a fast phase 
wherein monomers quickly convert to oligomers, causing a rapid drop in the monomer 
concentration. Because the critical and supercritical concentrations set the relative free 
energies of the monomer, oligomer, and fibril (see eq 2), the mass fraction of monomers 
immediately following the initial fast equilibration phase depends on the total protein 
concentration, not the presence of a barrier. Thus, at the end of the fast phase, the monomer 
concentrations are the same in Figures 5a and 5c at 150 μM and Figures 5b and 5d at 500 
μM. At 150 μM, the peptide concentration is smaller than the supercritical concentration, 
i.e., ctot < csup, and thus the oligomers are less thermodynamically stable than the monomer. 
As a result, most of the protein remains monomeric and only a small fraction of proteins 
form oligomers. At 500 μM, the peptide concentration is higher than the supercritical 
concentration, i.e., ctot > csup, and so the oligomer is stable relative to the monomer, and 
most of the monomer mass fraction converts into oligomers. Also seen in Figure 5 is that the 
mass fraction of oligomers decays concomitantly with the formation of the fibrils, regardless 
of concentration or ΔG‡. At long times, when only the fibril state is significantly populated, 
the monomer concentration is nearly zero because the critical concentration is 100 nM.
While the initial concentrations of oligomers are solely set by the total protein concentration 
relative to the supercritical concentration, the kinetics and time-dependent mass fractions 
differ dramatically for the simulations with and without a barrier. Without a barrier (Figures 
5a,b), the concentration of oligomers steadily drops during the lag phase. The steady loss 
occurs because, as oligomers of a critical nucleus n form, they are immediately available to 
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begin templating monomers into a fibril, i.e., “seeding” fibril formation. With a barrier 
(Figures 5c,d), oligomers cannot seed fibril formation until they cross the barrier, 
corresponding to a structural refolding event, so that the concentration of seeds that template 
fibril formation is smaller than that of oligomers, set by the Boltzmann factor and the barrier 
height. Therefore, when a barrier is present, there are fewer seeds than oligomers, and so 
fibril formation is slower. As a result, the oligomer mass fraction is roughly constant during 
the lag phase in the simulations with a barrier (Figure 5c,d).
Notice also that the β-sheet kinetics are much more sigmoidal when a barrier is present. 
Powers showed, for a barrier free model, that fibril kinetics become more exponential and 
less sigmoidal when the initial peptide concentration exceeds the supercritical concentration.
13
 Our model does as well (See Figure S4), but also predicts that sigmoidal kinetics can still 
occur for ctot > csup when a barrier is present. That result is another consequence of having 
fewer seeds than oligomers. Thus, with a barrier, it is possible to have both a large mass 
fraction of oligomers as well as sigmoidal kinetics, which is what we observe 
experimentally.
For comparison to experiment, Figures 5e–h show kinetic plots created by using the mass 
fractions from Figures 5a–d to weight algebraic sums of the simulated 2D IR spectra from 
Figure 3. The sums are then processed in a manner identical to the experimental data for 
comparison to Figure 1d and Figure 2. Superimposed on each plot, is the time-dependence 
of the fibril mass fraction. These plots illustrate that the experiments will appear as either 
two-state or three-state kinetics, depending on the initial conditions and the model. If the 
model has no barrier, ΔG‡ = 0, then graphs approximating two-state kinetics will be 
observed regardless of initial conditions (Figure 5e,f). At 150 μM, the oligomer mass 
fraction will be difficult to measure experimentally, and so a step-transition is observed from 
monomer to fibril. At 500 μM, the mass fraction of the oligomer is large, but would only be 
observed transiently at the very beginning of the kinetics, because its population decays so 
quickly. Thus, without a barrier, we would expect to see kinetics that largely appear two-
state from monomers to fibrils.
With a 6 kcal/mol barrier, two-state kinetics are still observed at 150 μM (Figure 5d) for a 
similar reason as the case without a barrier: the population of the oligomeric intermediate is 
much smaller than the monomers during the lag phase and the fibrils once they have formed. 
In contrast, three-state kinetics would be observed at 500 μM, with the oligomer having a 
distinct, strong absorbance throughout the lag phase. Thus, performing experiments at 
concentrations above the supercritical concentration produces 2D IR signals that can 
compete with the signals from the monomer and fibril species for oligomers with a free 
energy barrier, which is what we see experimentally.
Within the parameters of our model, the experimental data for hIAPP aggregation can only 
be explained by including a free energy barrier in the kinetic mechanism. The simulations 
with ΔG‡ = 6 kcal/mol in Figure 5g,h very closely resemble the experimental data in Figure 
2a and c (the 500 and 150 μM experimental data). Varying the constants in our model, we 
find that ΔG‡ must be greater than 3 kcal/mol to create a population of oligomers that agrees 
with experiment. Oligomer nucleus sizes of n = 7 to 15 all produce spectra and kinetics in 
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qualitative agreement with experiments. It is possible that nuclei of multiple sizes could 
participate in the aggregation process; our kinetic modeling suggests they would consist of 7 
to 15 hIAPP peptides, though our model does not include ensembles that contain a 
distribution of sizes. If ΔG‡ = 0, we cannot simulate sigmoidal curves that have both a 
significant lag time and an appreciable amount of oligomer mass fraction, nor do we observe 
sigmoidal kinetics for overall fibril aggregation at concentrations above csup, which we do 
observe experimentally. Since the data at 150 μM did not resolve an oligomeric intermediate, 
variables in the model can be adjusted to reproduce the relative lag time and sigmoidal 
kinetics for this concentration, but those variables do not produce a high enough mass 
fraction of oligomers to agree with experiments at higher concentrations. Thus, the 
experimental measurement of the oligomer concentration, even if only approximate, 
provides a very stringent condition for the modeling.
DISCUSSION
The 2D IR spectra of 13C18O labeled FGAIL in hIAPP clearly resolves a structure during 
the lag time that is neither the monomer nor fibril states. The data and simulations are 
consistent with an oligomeric species forming within the first few minutes that persists until 
the sigmoidal rise of the fibrils. From previous work on single-labeled FGAIL, we know that 
this intermediate is on-pathway to the fibril.50 On- and off-pathway intermediates are 
usually difficult to discern from kinetics alone. In earlier work, we established that the 
intermediate was on-pathway using an I26P mutation to destabilize the FGAIL intermediate, 
which slowed fibril formation >10-fold. Macrocycles that promote β-sheet formation were 
also consistent with an on-pathway intermediate.
No fibrils are observed in TEM images collected during the lag phase (see SI). The kinetics 
and populations in the current study can only be modeled if an additional, concentration 
independent, free energy barrier is included between the oligomer and fibril state. Without 
an additional barrier, associated with structural rearrangement, the experimental data cannot 
be reproduced with regards to the duration of the lag phase, sigmoidal kinetics, the presence 
of appreciable oligomer concentrations, nor the stable population of oligomer. With a >3 
kcal/mol barrier, very good agreement with experiment is found.
The inclusion of an explicit free energy barrier, representing an additional kinetic refolding 
step between the oligomer and fibril states, is not common for nucleation models. Figure 6a 
schematically illustrates the free energy landscape for a nucleated polymerization model that 
is the most common description for amyloid fibril formation, such as that of Powers and 
Powers.13 The x-axis is the number of associated polypeptides, which is 1 for the monomer, 
n for the critical size of the oligomeric nucleus, and n + 1 or greater for the fibril. The 
characteristics of these free energy surfaces depend on the protein concentration, ctot. To 
compare the surfaces, they are calculated relative to the free energy of the monomers. As 
explained above (eq 2), if ctot < csup, then it is thermodynamically unfavorable for oligomers 
to form. Likewise, if ctot < csup, then it is unfavorable for fibrils to form. Thus, the relative 
values of csup and ccrit give rise to 3 scenarios for the free energy landscape. If ctot is smaller 
than both csup and ccrit, then fibril formation is entirely uphill (blue curve). If ctot is larger 
than both csup and ccrit, then it is entirely downhill for fibril formation (red curve). If ctot lies 
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in between csup and ccrit (green curve), the oligomers effectively serve as a transition state 
that is the barrier to refolding into the fibril conformation. Figure 6 schematically illustrates 
the scenarios.
According to the classical nucleation model, the free energy landscape for ctot = 500 and 250 
μM would be entirely downhill (red curve). Thus, formation of both the oligomers and fibrils 
is spontaneous, creating very fast kinetics and a low population of oligomers at these 
concentrations. The free energy landscape at ctot = 150 μM would have an uphill oligomer 
and downhill fibril free energy (green curve). Because the oligomer is energetically uphill, 
only a small percentage of proteins will form oligomers (Figure 5a), and so the kinetics of 
fibril formation will be slow. Thus, in the nucleated polymerization model, it is not possible 
to generate high populations of oligomers for extended periods of time, because the 
oligomers are either unlikely to form or, if they do form quickly, they rapidly convert to 
fibrils. We could not fit our data with such a model.
To create a kinetic scheme that fits our data, we added a refolding barrier that is 
concentration independent, as shown schematically in Figure 6b. The idea is that the 
assembly of the n proteins into the oligomeric species is necessary, but not sufficient, for 
fibril formation. This free energy landscape reproduces our data. In our model, the barrier 
does not alter the free energy of the oligomers. Instead, it slows the formation of fibrils by 
kinetically trapping the oligomers, even when both the oligomers and fibrils are downhill 
(Figure 6b, red). At concentrations of ctot > csup and a >3 kcal/mol barrier, sigmoidal 
kinetics can occur with long lag times and an easily measurable population of oligomers. At 
lower concentrations when ctot < csup, the barrier still slows the kinetics of fibril formation, 
but does not increase the population of oligomers appreciably because they are already 
energetically uphill compared to the monomer. Models that postulate a free energy barrier 
between the monomer state and the oligomeric state, (e.g., “activated monomer” models),
20,80,81
 would also not reproduce our data, because a monomer activation energy would not 
produce both long lag times and appreciable mass fractions of oligomers.
Because we observe an intermediate over a long period of time, we conclude that the 
oligomeric species observed experimentally does not have the correct structure to seed fibril 
formation, in agreement with the simulations. Rather, the oligomer must restructure prior to 
acting as a seed to template additional monomers, and the process of restructuring creates a 
free energy barrier.
The barrier simulated here, >3 kcal/mol, is in the range that one might expect for a 
moderately sized protein. The change in free energy associated with unfolding a globular 
protein like myoglobin is about 10.5 kcal/mol.85,86 Similarly, the free energy of unfolding a 
leucine rich repeat domain (from the virulence factor Internalin B) containing seven short β-
strands (each followed by a tight turn and an α-helix) is ca. 4 kcal/mol.87 If the oligomer has 
n = 10 peptides, as we model, and if the only significant contacts between peptides are due 
to the observed FGAIL β-sheet, then there would be 50 hydrogen bonded residues 
contributing to the stability of the oligomer. It may not be necessary to completely unfold the 
intermediate prior to forming the fibril and so the complete unfolding of the intermediate 
may be higher than the free energy barrier determined here.
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Structures consistent with our experimental results are shown in Figure 7, taken from a 
molecular dynamics simulation that used replica exchange to map the free energy landscape 
for a dimer of hIAPP,50 and arranged into a postulated aggregation mechanism. The pathway 
starts with disordered peptides and ends in a fibril state with N- and C-terminal β-sheets. 
Also shown is a structure in which the FGAIL region forms a parallel β-sheet.50,75 We also 
include in this pathway a structure taken from the MD simulations in which the FGAIL β-
sheet is not fully formed nor are the fibril β-sheets (labeled “‡?”). A structure such as this 
(but containing more strands) may be on-pathway between the FGAIL intermediate and the 
fibril. It would presumably be higher in free energy than either the FGAIL intermediate or 
the fibrils, and therefore a transition state on the free energy surface. Other partially formed 
structures in the MD simulations are also consistent with a free energy transition state. To 
link the steps in this proposed aggregation mechanism with the kinetic model, we have 
added the shapes from Figure 4 to each of the structures (the structure of the fibril in Figure 
7 is shown as a trimer for consistency with the kinetic model). As we noted above, the actual 
oligomers are much larger than a dimer and may contain other secondary and tertiary 
structures. The mechanism presented here is intended to provide a conceptual link between 
the kinetics and molecular structures that is self-consistent with the available experimental 
data. In essence, the oligomer needs to refold, and thus, the landscape should also include 
the free energy associated with this protein folding event.
The free energy cost of restructuring the oligomer should be independent of concentration, 
analogous to the refolding of a single complex protein. The barrier height might depend on 
oligomer size, which could be tested with kinetic models that allow for more than one 
oligomer nucleation size, n. A refolding barrier in the free energy landscape that is 
independent of concentration has implications for aggregation under physiological 
conditions, albeit in vivo conditions are much more heterogeneous and complex than our in 
vitro conditions. It has been estimated that the protein content of hIAPP in the β-cells of the 
islets of the pancreas may be as large as 500 μM to 5 mM.88 If so, then the protein 
concentration would exceed the supercritical concentration, causing appreciable amounts of 
oligomers. The exact intracellular concentration of human amylin is not known, but the 
concentration of amylin is high in the intracellular environment of the β-cell and is likely to 
initially be high in the extracellular environment where it forms amyloid. Amylin is 
produced by the β-cells and is stored within the insulin secretory granule prior to release. 
Within the granule, amylin is located in the halo region (insulin occupies the dense core 
region) and its concentration within the granule in normal, nondiabetic subjects has been 
estimated to be between 500 μM to 5 mM,39,88,89 although other compounds are present in 
the granule that are believed to inhibit aggregation.39,89,90 Amylin is released to the 
extracellular space when the secretory granules fuse to the plasma membrane. Multiple 
vesicles release their contents simultaneously, which could create a spike in concentration. 
In vivo extracellular amyloid fibrils in humans and in animal models are initially deposited 
in the restricted confined space between pericapillary regions of the islet between the two 
basement membranes.90,91 Thus, there will be an initial high local concentration released to 
a confinded space. High concentrations of amylin in vitro are clinically relevant as well. 
Amylin is deficient in both type 1 and type 2 diabetes patients and amylin analogs are a 
promising adjunct to insulin therapy.92 An improved understanding of amylin amyloid 
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formation and aggregation at the concentrations used for storage of peptide therapeutics is 
required for the rational design of soluble amylin analogs for clinical applications.92
Even if the soluble fraction of hIAPP is lower than the supercritical concentration, a free 
energy barrier associated with refolding extends the lifetimes and stabilizes the population of 
oligomers. If toxicity is caused by a structurally well-defined oligomer, then a long lifetime 
seems necessary, because the proteins need to diffuse to the cellular interface. Indeed, if 
oligomers were not long-lived, then they would be exceedingly difficult to be recognized by 
antibodies, which is not the case. Moreover, in our model, the oligomer has a distinct 
secondary and tertiary structure that might be targeted by small molecule therapeutics. 
Indeed, we have previously demonstrated that IAPP oligomers can be targeted with a 
rationally designed macrocyclic non-natural peptide.50
SUMMARY AND CONCLUSIONS
The most common means for testing kinetic models for amyloid fibril formation, and 
thereby characterizing their free energy landscapes, is to perform a series of concentration 
dependent studies in which fibril formation is followed as a function of time, such as with 
Tht fluorescence assays. For simple free energy landscapes that correspond to classical 
nucleation-polymerization kinetic models, one can back out from these measurements the 
size of the nucleating species and the rate of fibril elongation. However, it is unlikely that 
Tht fluorescence alone has the necessary experimental information to constrain and test 
more sophisticated kinetic models corresponding to more complex free energy landscapes. 
In fact, as structural information about fibrils and oligomers becomes available, it is 
becoming increasingly apparent that there must be significant changes in the structures of 
some proteins during aggregation. These intermediate structures are of much interest, 
because they have been implicated as toxic species and it may be possible to inhibit their 
formation. Thus, models that unify structures and kinetics are needed. 2D IR spectroscopy 
probes both structure and kinetics, and thereby provides additional experimental observables 
to build such models. Our kinetic modeling demonstrates that a concentration independent 
free energy, associated with refolding, connecting the nucleus and fibril states is needed to 
produce a qualitatively accurate model of the experimental data, akin to the “monomer 
activation” model once used for describing actin filamentation, but applied to oligomers,
20,80,81
 i.e., an “oligomer activation” model. The physical origin of this barrier is intuitively 
understood as a necessary structural rearrangement of the oligomer prior to adopting a 
structure that can elongate into a fibril by templating monomers. The structural free energy 
barrier is at least 3 kcal/mol and is attributed to the disruption of a ordered β-sheet formed 
by the FGAIL residues in the oligomers and refolding into the “disordered loop” of the fibril 
and probably includes other structure changes not measured here. An upper bound for the 
barrier height cannot be given, but a range of larger barriers can agree qualitatively with our 
experimental results. Beyond monomer activation models, the presence of a concentration 
independent, structurally associated free energy barrier at the boundary between oligomers 
and fibrils is a relatively unexplored approach in modeling nucleated amyloid fibril growth. 
Our results suggest that the thermodynamics of protein folding can alter the free energy 
landscape enough to modify the kinetics of amyloid formation. In addition, we show that 
working at concentrations above the supercritical concentration, a significant population of 
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oligomers can be formed, thereby providing an experimentally tractable way to study their 
structures and properties as well as determine the free energy cost of refolding the oligomer 
into the structure of the fibril. Though we do not speculate as to whether our results extend 
to other amyloidogenic proteins, based on known structures of oligomers and fibrils, we 
anticipate that this concept might be applicable to many other amyloid forming proteins as 
well.
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(a–c) 2D IR spectra of the isotopically labeled Amide-I vibrations of 0.5 mM FGAIL-
labeled hIAPP in 20 mM phosphate buffer in the isotope labeled region at the indicted times 
after initiation of aggregation, and (d) as diagonal cuts through the fundamental transition in 
the 2D spectra as a function of time after initiation. Blue and red features correspond to 
negative and positive signals, respectively.
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Series of diagonal cuts through the hIAPP fundamental transition in the isotope labeled 
region of the 2D IR spectra collected at 500 (a), 250 (b) and 150 μM (c) concentration in 20 
mM phosphate buffer as a function of time after initiation of aggregation. Trace of the 
amplitude of the unlabeled Amide-I band (1620 cm−1) are overlaid for comparison with the 
time scale of fibril formation.
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Simulated 2D IR spectra generated using ensembles of structures and standard coupling 
models. (a) Random coil spectrum modeled using a self-avoiding poly peptide chain 
adhering to the Ramachandran distribution provided by the Top 500 database nonsecondary 
structure distribution.70 (b) 5-Stranded β-sheet oligomer. (c) 10-Stranded β-sheet with 
disordered F and G residues to model the loop of hIAPP fibrils. The amylin sequence is 
shown above with the FGAIL residues highlighted.
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Cartoon summary of the kinetic model that best described the experimental observations. 
Monomers (orange) can form an oligomer (green ovals) that can undergo a conformational 
change into a fibril “seed” (green parallelograms) with free energy cost of ΔG‡. The seeds 
grow into fibrils (blue) that can autocatalyze through a fragmentation mechanism.
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Results of kinetic modeling describing (a,b) mass fractions for monomer, oligomer, and 
fibril as a function of time at 150 μM and 500 μM concentrations with no free energy barrier 
between the nucleus and the fibril, and (c,d) when a 6 kcal/mol free energy barrier is present 
between the nucleus and fibril states. Panels (e–h) show the corresponding predicted 2D IR 
signal intensities produced by weighting the calculated 2D spectra for the monomer, 
oligomer, and fibril by the kinetic populations in panels (a–d). The parameters used in the 
plotted simulations were ccrit = 100 nM, csup = 250 μM, and n = 10.
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Schematic free energy diagrams for fibril growth in different concentration regimes for (a) 
classical nucleated fibril formation, and (b) nucleated fibril formation with a concentration 
independent free energy barrier incorporated between the nucleus and fibril states.
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A schematic representation of the structural changes that occur during hIAPP aggregation. 
The structures of the monomer, intermediate, and potential transition state structure (‡?) 
were taken from a molecular dynamics simulation that used replica exchange to map the free 
energy landscape of a dimer of hIAPP.50 The FGAIL sequence is colored red. The fibril 
structure uses the solid state NMR structure of Luca et al.75 and is a trimer to be consistent 
with the kinetic model. Colored shapes from Figure 4 are assigned to each structure to 
illustrate the link to the kinetic model. Structures other than the one shown here might be 
consistent with forming the free energy transition state. We note that the experimental data is 
consistent with an oligomer that is at least pentameric.
Serrano et al. Page 25
J Am Chem Soc. Author manuscript; available in PMC 2018 March 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
